Chapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection
Balasubramanian P, Inzucchi S. Chapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. 2023, 337-363. DOI: 10.1016/b978-0-323-99991-5.00006-1.Peer-Reviewed Original ResearchSGLT2 inhibitorsType 2 diabetesSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsLarge cardiovascular outcome trialsInduction of glucosuriaRenal protective benefitsCardiovascular risk factorsGlucose-lowering medicationsCardiovascular outcome trialsCotransporter 2 inhibitorsClinical practice guidelinesMechanism of actionRenal benefitsCardiorenal benefitsDiabetes statusOutcome trialsBlood pressureChronic kidneyHeart failureRisk factorsLipid profileCardiovascular diseasePractice guidelinesBody weightEmpagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Balasubramanian P, Wanner C, Ferreira J, Ofstad A, Elsaesser A, Zinman B, Inzucchi S. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? Medicine Of Ukraine 2022, 48-52. DOI: 10.37987/1997-9894.2022.5-6(261-2).271666.Peer-Reviewed Original ResearchIncidence rate ratiosT2D patientsClinical trialsStone eventsGLP-1 receptor agonistsLarge cardiovascular outcome trialsEMPA-REG OUTCOMESGLT2 inhibitor empagliflozinCardiovascular outcome trialsProspective clinical trialsSGLT2 inhibitor useRisk of nephrolithiasisAnnual incidence rateRandomized clinical trialsType 2 diabetesRelative risk estimatesEmpagliflozin therapyInhibitor empagliflozinInhibitor useOutcome trialsDiabetes mellitusSGLT2 inhibitionReceptor agonistRisk factorsIncidence rate